Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05218499
Title Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Boehringer Ingelheim
Indications

dedifferentiated liposarcoma

Therapies

BI 907828

Doxorubicin

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

Additional content available in CKB BOOST